癌症研究
肿瘤微环境
免疫系统
细胞毒性T细胞
结直肠癌
化学
CD8型
间质细胞
免疫疗法
癌症免疫疗法
免疫原性细胞死亡
下调和上调
克拉斯
癌细胞
细胞外
细胞毒性
免疫学
免疫抑制
细胞培养
转移
T细胞
整合素
细胞外基质
癌症
抗原
调解人
先天免疫系统
细胞疗法
癌相关成纤维细胞
作者
Sijia Chen,Lishan Wang,Linzhe Su,Luyao Zhang,Yun Zhu,Hongwen Liu,Ge Bai,Xinqian Meng,Lei Xu,Mei Wang,Yuhua Tian,Yue Zhou,Lei Wang
摘要
ABSTRACT Colorectal cancer (CRC) exhibits intrinsic resistance to conventional therapeutic regimens. By integrating single‐cell and bulk transcriptomic data from CRC cohorts, we demonstrate that proliferative capacity alone constitutes an inadequate prognostic predictor. Instead, an immunosuppressive tumor microenvironment (TME) emerges as the dominant driver of disease progression. Galectin‐1 (LGALS1), highly upregulated in metastatic CRC, correlates with robust infiltration of regulatory T cells (Tregs) and M2 macrophages to facilitate immune evasion and poor clinical outcomes, thereby serving as a promising therapeutic target for anti‐tumor immunotherapy. The stromal barrier mediated by cancer‐associated fibroblasts (CAFs) restricts intratumoral penetration of antitumor agents and diminishes therapeutic efficacy. To overcome this physical barrier, we constructed a CAF extracellular vesicle‐based co‐delivery platform termed CEV@Comb, encapsulating the LGALS1 inhibitor OTX008 and 5‐fluorouracil (5‐FU). CEV@Comb selectively accumulates in tumors, suppresses growth in vitro and in vivo, and remodels the immunosuppressive TME by boosting M1 macrophages and cytotoxic CD8 + T cells while reducing intratumoral Tregs. Combination therapy with CEV@Comb and anti‑programmed death‑1 antibody (αPD‐1) further amplifies anti‐tumor immunity in the Apc −/− , Kras G12D , Trp53 −/− , Smad4 −/− (AKPS) CRC mouse model. This study identifies LGALS1 as a core immunosuppressive mediator and provides an innovative chemoimmunotherapeutic strategy to improve clinical outcomes for patients with advanced CRC.
科研通智能强力驱动
Strongly Powered by AbleSci AI